Evidence map›Paper›PMID 38862929›Full record

ArticleBMC public health2024

Hepatitis B discrimination: global responses requiring global data.

Catherine Freeland, Anousha Qureshi, Jack Wallace, Kenneth Kabagambe, Hailemichael Desalegn, Chris Munoz, Dee Lee, Theobald Owusu-Ansah, Danjuma Adda, Gibril Ndow and 5 more

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Time for a globally unified chronic HBV terminology?JHEP reports : innovation in hepatology · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Catherine FreelandHepatitis B Foundation, Doylestown, PA, USA. Freeland@hepb.org.
Anousha QureshiHepatitis B Foundation, Doylestown, PA, USA.
Jack WallaceCoalition to Eradicate Viral Hepatitis in Asia Pacific, Singapore, Singapore.
Kenneth KabagambeThe National Organisation for People Living with Hepatitis B (NOPLHB), Kampala, Uganda.
Hailemichael DesalegnSt.Paul's Hospital Millenium Medical College, Addis Ababa, Ethiopia.
Chris MunozYellow Warriors Society of the Philippines, Baguio, Philippines.
Dee LeeInno Community Development Organisation, Guangzhou, China.
Theobald Owusu-AnsahHepatitis Foundation of Ghana, Accra, Ghana.
Danjuma AddaWorld Hepatitis Alliance (WHA), London, UK.
Gibril NdowMedical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine, Serrekunda, Gambia.
Sarra YousifPublic Health Unit, Population Health, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Hala AbdallaPublic Health Unit, Population Health, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Omer KheirPublic Health Unit, Population Health, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Thomas TuStorr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney at Westmead Hospital, Westmead, Australia.
Chari CohenHepatitis B Foundation, Doylestown, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 250 million individuals live with chronic hepatitis B (CHB) infection worldwide. A significant proportion of these people often face discrimination defined as the unjust, unfair, or prejudicial treatment of a person on the grounds of their hepatitis B status. Hepatitis B related discrimination has not been widely documented in the literature. This study aims to describe the lived experience of discrimination, document its impact, and shed light on its consequences. A hepatitis B discrimination registry was launched to record self-reported discrimination associated with hepatitis B. The registry included brief demographic questions (age, gender, country of origin), discrimination-specific questions (where, when, and how discrimination occurred), and open-ended questions to detail specific experiences. The registry was distributed to hepatitis B patient/people-focused listservs, social media networks, and community-based organizations around the globe. Descriptive data were analyzed including comparative analysis by country and type of discrimination occurring along with qualitative data (open-ended responses) which were analyzed using thematic analysis techniques A total of 569 individuals responded to the survey between May 2021 and December 2023. Individuals identified as residing in the Philippines (34%; N = 194), Nigeria (11%; N = 60), Pakistan (8%; N = 45), India (6%, N = 34), Uganda (5%; N = 31), the United States of America (4%, N = 26), Ghana (3%; N = 15), Ethiopia (2%; N = 14), and other countries in smaller number with a total of 65 countries reported discrimination at least by one individual. Of these, 461 individuals shared details about their experiences of discrimination with most relating to restrictions on access to work visas, followed by in-country hepatitis B-related employment restrictions, educational-based discrimination, discrimination within the community and health facilities, and the emotional impact of hepatitis B discrimination. This is the largest primary collection of hepatitis B-associated discrimination events and highlights how hepatitis B discrimination clearly has a significant impact on individuals' lives and limits economic opportunities regardless of physical symptoms. Such impacts likely act as barriers to diagnosis and engagement in care, so need to be addressed to achieve the global hepatitis B elimination goals. The data highlight a need for global, national responses and more systematic responses to discrimination experienced by people with hepatitis B.

Indexed as

Global HealthHepatitis B, ChronicAdolescentAdultFemaleHumansMaleMiddle AgedRegistriesSocial DiscriminationSurveys and QuestionnairesYoung AdultDiscriminationHepatitis BLiver cancerLiver diseaseStigmaViral hepatitis

Identifiers

PMID38862929
PMCPMC11167835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.